This chapter aims to summarize the clinical results of these first-generation of TKIs published thus far.doi:10.1007/978-1-4939-1622-1_8HanHsiWongTimEisenHanHsiWongTimEisenSpringer New YorkWong HH, Eisen T. First-generation tyrosine kinase inhibitors: clinical results. In: Renal Cell Carcinoma....
First-Generation EGFR Tyrosine Kinase Inhibitors Associated With Poorer Progression-Free Survival vs Conventional Chemotherapy in EGFR Wild-Type NSCLCMatthew Stenger
7. Claudiani S, Chughtai F, Khan A. et al. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance. Leukemia. 2024;38:796–802. doi:...
For years, ibrutinib (Imbruvica) had been a cornerstone inchronic lymphocytic leukemia (CLL)treatment. Given the recent U.S. Food and Drug Administration approval of newer-generation Bruton tyrosine kinase (BTK) inhibitors such aszanubrutinib (Brukinsa)andpirtobrutinib (Jaypirca...
The present study investigated the various features that might influence the overall survival (OS) of patients with metastatic renal cell carcinoma (RCC) treated with first-line tyrosine kinase inhibitors (TKIs). Patients and Methods A retrospective analysis was performed of consecutive patients with me...
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in JapanEarly Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predi...
Lin et al Dovepress patients.2 During the past decade, results from multiple Phase III clinical trials have identified the first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib, icotinib as the first-line therapy for patients with EGFR-mutant advanced NSCLC.3...
Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitorsdoi:10.1158/0008-5472.CAN-10-... - 《Cancer Research》 被引量: 0发表: 2011年 Generation of mesenchymal stromal cells Mesenchymal stromal cells (MSC) of bone marrow ori- ...
Everolimus must be considered after first-line failure of a tyrosine kinase inhibitor (TKI); furthermore, recent evidence suggests sequential use of TKIs ... E Herrmann,S Bierer,C Wülfing - 《World Journal of Urology》 被引量: 86发表: 2010年 Treatment outcome with mTOR inhibitors for metastat...
Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)doi:10.1007/s40259-014-0093-2Elisabetta...